ChatGPTを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。この１年、病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。
<><><>
<>
24/06/22
[HTML] Single‐cell combined with transcriptome sequencing to explore the molecular mechanism of cell communication in idiopathic pulmonary fibrosis
M Zhu, Y Yi, K Jiang, Y Liang, L Li, F Zhang, X Zheng… - Journal of Cellular and …, 2024
… Idiopathic pulmonary fibrosis is the most common and common type of pulmonaryfibrosis. Global statistics indicate that five million individuals suffering from IPF worldwide. With exacerbating factors like environmental pollution and novel …
Progress in the radiologic diagnosis of idiopathic pulmonary fibrosis
RE Ledda, C Marrocchio, N Sverzellati - Current Opinion in Pulmonary Medicine
… Idiopathic pulmonary fibrosis (IPF) is a chronic progressive and irreversible … pulmonary fibrosis can be detected on chest radiography [3], high resolution computed tomography (HRCT) of the chest remains the modality of choice to identify …
- 特発性肺線維症の放射線診断の進歩
Risk of Suicide in Individuals with Idiopathic Pulmonary Fibrosis: A Nationwide Cohort Study
BG Kim, K Han, JH Jung, DW Park, SH Kim, JW Sohn… - American journal of respiratory …
Risk of Suicide in Individuals with IdiopathicPulmonary Fibrosis: A Nationwide Cohort Study Risk of Suicide in Individuals with IdiopathicPulmonary Fibrosis: A Nationwide Cohort Study Am J Respir Crit Care Med. 2024 Jun 18. doi: 10.1164/rccm.202404-0767RL …
- 特発性肺線維症患者の自殺リスク：全国コホート研究
… [2, 1-c][1, 4] benzodiazepine-3, 11-dione (PBD) derivatives as selective HDAC6 inhibitors for the efficient treatment of idiopathic pulmonary fibrosis (IPF) in vitro and in …
Y Li, H Yang, X Zhao, X Zhao, J Quan, L Wang, E Ma… - European Journal of …, 2024
… Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by a progressive fibrotic phenotype. Immunohistochemical studies on HDAC6 overexpression in IPF lung tissues confirmed that IPF … , the most common is …
- 特発性肺線維症（IPF）のin vitroおよびin vivoでの効率的な治療のための選択的HDAC6阻害剤としての新しいピロロ[2,1-c][1,4]ベンゾジアゼピン-3,11-ジオン（PBD）誘導体の発見
[HTML] Kynurenine acts as a signaling molecule to attenuate pulmonary fibrosis by enhancing the AHR-PTEN axis
Y Wang, GR Wu, H Yue, Q Zhou, L Zhang, L He, W Gu… - Journal of Advanced …, 2024
… We demonstrated that high levels of Kyn are a clinical feature in both idiopathic PF patients and primary Sjögren syndrome associated PF patients. Further studies illustrated that Kyn served as a braking molecule to suppress fibroblast functionality …
- キヌレニンはAHR-PTEN軸を強化することで肺線維症を軽減するシグナル分子として作用する。
PKM2/Hif-1α signal suppression involved in therapeutics of pulmonary fibrosis with microcystin-RR but not with pirfenidone
Y Ren, J Wang, W Guo, J Chen, L Xu, Z Wu, Y Wang - Toxicon, 2024
… to be given conditional recommendation in idiopathic pulmonary fibrosis (IPF) therapies with slowing disease … for pulmonary fibrosisin medicine. Previous studies have demonstrated that microcystin-RR (MC-RR) effectively alleviates …
- PKM2/Hif-1αシグナル抑制はミクロシスチン-RRによる肺線維症の治療に関与しているが、ピルフェニドンでは関与していない
Syndromic genetic causes of pulmonary fibrosis
R Borie, I Ba, MP Debray, C Kannengiesser, B Crestani - Current Opinion in Pulmonary …
… Impaired CMV immunity in idiopathicpulmonary fibrosis lung transplant recipients with short … No effect of danazol treatment in patients with advanced idiopathic pulmonaryfibrosis. ERJ … Lung transplantation for idiopathic pulmonary fibrosis …
- 肺線維症の症候群性遺伝的原因
[PDF] Noninvasive assessment of the lung inflammation-fibrosis axis by targeted imaging of CMKLR1
PZ Mannes, TS Adams, S Farsijani, CE Barnes… - Science Advances, 2024
… By analyzing single-cell RNA sequencing datasets, we demonstrated CMKLR1 expression as a transient signature of monocyte-derived macrophages (MDMφ) enriched in patients with idiopathic pulmonary fibrosis (IPF). Consistently, we …
- CMKLR1の標的イメージングによる肺の炎症-線維化軸の非侵襲的評価
[HTML] Stem cell-based therapy for fibrotic diseases: mechanisms and pathways
M Taherian, P Bayati, N Mojtabavi - Stem Cell Research & Therapy, 2024
… idiopathic pulmonary fibrosis. Besides, the overactivation of immune responses during any inflammatory condition causing tissue damage could contribute to the pathogenic fibrotic events accompanying the healing response; for instance, the …
- 線維性疾患に対する幹細胞療法：メカニズムと経路
24/06/21
[HTML] Current state of signaling pathways associated with the pathogenesis of idiopathic pulmonary fibrosis
Y Zhou, T Ling, W Shi - Respiratory Research, 2024
… Idiopathic Pulmonary Fibrosis (IPF) represents a chronic and progressive pulmonary disorder distinguished by a notable mortality … IPF, both within national and international contexts. The objective is to enhance the comprehension of the …
- 特発性肺線維症の発症に関連するシグナル伝達経路の現状
[HTML] Mitigation of Oxidative Stress in Idiopathic Pulmonary Fibrosis Through Exosome-Mediated Therapies
Z Wang, Y Zhang, X Li - International Journal of Nanomedicine, 2024
… Idiopathic pulmonary fibrosis (IPF) presents a complex and debilitating pulmonary … Citation2 The insidious nature of IPF lies in its capacity to progressively diminish lung function, … The pathogenesis of IPF unfolds through an intricate cascade of …
- エクソソームを介した治療による特発性肺線維症における酸化ストレスの緩和
[HTML] Treating sleep-disordered breathing of idiopathic pulmonary fibrosis patients with CPAP and nocturnal oxygen treatment. A pilot study
J Bordas-Martinez, N Salord, V Vicens-Zygmunt… - Respiratory Research, 2024
… a major comorbidity in idiopathic pulmonaryfibrosis (IPF) and is associated with a poor outcome. There is a lack of knowledge regarding the impact of SDB treatment on IPF. We assessed at one year: (1) the effect of CPAP and/or nocturnal oxygen …
[PDF] Evaluation of Diagnostic Value of the Bronchoalveolar Lavage in Cases of Interstitial Lung Diseases at a Tertiary Care Centre
PK Narukulla - Sarcoidosis
… Cryptogenic fibrosing alveolitis has been removed, leaving the term idiopathicpulmonary fibrosis (IPF). … with idiopathicpulmonary fibrosis. Am J Respir Crit Care Med. 2015;192:1475–82. … An official ATS/ERS/JRS/ALAT statement: idiopathic …
- 三次医療センターにおける間質性肺疾患症例における気管支肺胞洗浄の診断価値の評価
24/06/20
[PDF] Self-Learning e-Skin Respirometer for Pulmonary Disease Detection
A Babu, G Kassahun, I Dufour, D Mandal, D Thuau - Advanced Sensor Research, 2024
… asthma, idiopathic pulmonary fibrosis(IPF), and others.[15, 16] For instance, reduced tidal volume is indicative of impaired lung function or respiratory muscle weakness, while, elevated tidal volume gives information about hyperinflation or …
- 肺疾患検出のための自己学習型 e-Skin 呼吸計
24/06/19
[HTML] Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction
Z Zheng, F Peng, Y Zhou - Chinese Medical Journal Pulmonary and Critical Care …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease with a dismal prognosis. Early diagnosis, accurate … significant promise in IPFmanagement. In recent years, there has been a growing interest in identifying …
- 特発性肺線維症のバイオマーカー：現在の知見と将来の方向性
[PDF] Unveiling the role of copper metabolism and STEAP2 in idiopathic pulmonary fibrosis molecular landscape
Y Wang, S Chen, S Chen, J Jiang - Journal of Cellular and Molecular Medicine, 2024
… Idiopathic pulmonary fibrosis (IPF) is a debilitating interstitial lung disease characterized by progressive fibrosis and poor prognosis. Despite advancements in treatment, the pathophysiological mechanisms of IPF … Idiopathic pulmonary …
[HTML] ATP-induced fibrogenic pathway in circulating cells obtained by idiopathic pulmonary fibrotic (IPF) patients is not blocked by nintedanib and pirfenidone
C Colarusso, A Falanga, S Di Caprio, M Terlizzi… - Biomedicine & …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a severe disability due to progressive lung dysfunction. IPF has long been viewed as a non-immune form of pulmonary fibrosis, but … IL-1-like cytokines and ATP are highly detected in the lung and broncho-alveolar …
- 特発性肺線維症（IPF）患者の循環細胞におけるATP誘導線維形成経路は、ニンテダニブとピルフェニドンによって阻害されない
EE495 A Targeted Literature Review of Lung Function Decline in Idiopathic Pulmonary Fibrosis to Improve Survival Predictions in Cost-Effectiveness Analyses
OM Dong, W Herring, P Chopra, B Elpers… - Value in Health, 2024
… Cost-effectiveness (CE) models for idiopathicpulmonary fibrosis (IPF) treatments that have been submitted to the National Institute for Health … Our objective was to review the IPFdisease literature for compatibility with existing IPF mortality …
- 特発性肺線維症における肺機能低下に関する文献レビューによる費用対効果分析における生存予測の改善
Mortality trends in idiopathic pulmonary fibrosis in Europe between 2013 and 2018.
F Gonnelli, M Bonifazi, R Hubbard - The European Respiratory Journal, 2024
… In summary, the IPF mortality rate is increasing across Europe. There are currently more than 17 000 deaths recorded from IPFeach year in Europe but the marked geographical differences we observed suggest that this figure may …
- 2013 年から 2018 年までのヨーロッパにおける特発性肺線維症の死亡率の傾向。
PCR98 Suboptimal Dosing and Discontinuation of Antifibrotic Agents in Patients with Idiopathic Pulmonary Fibrosis (IPF)
P Pimple, SD Nathan, JJ Swigris, AL Olson, S Shetty - Value in Health, 2024
… Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrotic lung disease. Antifibrotic agents have demonstrated ability to slow IPF progression, but many patients adjust dose due to dosing complexity or discontinue therapy to manage …
- 特発性肺線維症（IPF）患者における抗線維化薬の不適切な投与と中止
Repetitive invasive lung function maneuvers do not accentuate experimental fibrosis in mice
T Röpke, F Aschenbrenner, L Knudsen, T Welte… - Scientific reports, 2024
… Assessment of lung function is an important clinical tool for the diagnosis and monitoring of chronic lung diseases, including idiopathicpulmonary fibrosis (IPF). In mice, lung function maneuvers use algorithm-based ventilation strategies including …
- 反復的な侵襲的肺機能操作はマウスの実験的線維症を悪化させない
[PDF] CSP7 protects alveolar epithelial cells by targeting p53-fibrinolytic pathways during chronic lung injuries
B Puthusseri, AK Bhagavath, D Korir, R Shetty…
… The loss of alveolar epithelial regeneration in patients with idiopathic pulmonary fibrosis(IPF) … mortality from idiopathic pulmonaryfibrosis in the twenty-first century. Ann Am Thorac Soc … length shortening in patients with idiopathic pulmonary …
- CSP7は慢性肺損傷時にp53線溶経路を標的として肺胞上皮細胞を保護する
24/06/18
Mendelian randomization study on the causal effect of herpes simplex virus infection on idiopathic pulmonary fibrosis
M Zhang, J Qiu, R Wang - Expert Review of Respiratory Medicine, 2024
… Previous observational studies have shown that past infection of herpes simplex virus (HSV) is associated with idiopathic pulmonaryfibrosis (IPF). The present study aims to identify the causal link between HSV infection (exposure factor) and IPF (outcome …
- 単純ヘルペスウイルス感染が特発性肺線維症に及ぼす因果関係に関するメンデルランダム化研究
[HTML] Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives
C Vancheri, E Sciacca, G Muscato, L Spicuzza… - Multidisciplinary Respiratory …, 2024
… Idiopathic pulmonary fibrosis (IPF) represents a fibrotic interstitial lung disease characterized by uncertain … of IPF. However, despite these advances, these drugs are not curative, although they can slow the natural progression of the disease. The …
- 特発性肺線維症の薬物治療：現状の課題と今後の展望
[HTML] Expression of HOXB7 in the Lung of Patients with Idiopathic Pulmonary Fibrosis: A Proof-of-Concept Study
AV Samarelli, R Tonelli, G Raineri, I Mastrolia… - Biomedicines, 2024
… the onset and progression of idiopathicpulmonary fibrosis (IPF) still need to … IPF, retrospectively selected from the IPF database of the University Hospital of Modena. HOXB7 expression was analyzed and compared with that of five patients with no …
- 特発性肺線維症患者の肺における HOXB7 の発現: 概念実証研究
Construction and Bioinformatics Analysis of ceRNA Regulatory Networks in Idiopathic Pulmonary Fibrosis
M Zhang, X Wu, H Zhu, C Fu, W Yang, X Jing, W Liu… - Biochemical genetics
… Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of pulmonary fibrosisof unknown etiology. Despite ongoing research, … (ceRNA) regulatory networks in IPFdevelopment. Therefore, this study investigated the ceRNA network …
- 特発性肺線維症における ceRNA 制御ネットワークの構築とバイオインフォマティクス解析
New Therapies in Outpatient Pulmonary Medicine
L Granados, M John, JD Edelman - Medical Clinics
Asthma is characterized by inflammation of airways and bronchial hyperresponsiveness that leads to variable airflow obstruction. 1–3 It is a heterogeneous disease that is diagnosed clinically through a detailed history and …
- 外来呼吸器内科における新しい治療法
24/06/17
[HTML] Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis
K Sugino, H Ono, M Saito, M Ando, E Tsuboi - PLOS ONE, 2024
… Switching anti-fibrotic treatment in patients with idiopathic pulmonary fibrosis (IPF) has not … Idiopathic pulmonary fibrosis (IPF) has a chronic and progressive course, eventually leading to … Moreover, because the clinical course is heterogeneous …
- 特発性肺線維症に対する抗線維化治療をニンテダニブからピルフェニドンに切り替えた場合の忍容性と有効性
[HTML] Genetic-informed proteome-wide scan reveals potential causal plasma proteins for idiopathic pulmonary fibrosis
J Zhu, H Liu, R Gao, R Gong, J Wang, D Zhou, M Yu… - Thorax, 2024
… Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease for which there are no reliable biomarkers or disease-modifying drugs. Here, … between 2769 plasma proteins and IPF. Our Mendelian randomisation analysis identified nine proteins …
Examining the Effectiveness of Combining Glutaredoxin and Pirfenidone on Lowering Fibrotic Markers
M Haley - 2024
… Glutaredoxin, which has shown promise in reversing the effects of IPF. We analyzed the effect of this combination on fibrotic markers’ … markers’ expression in IPF fibroblasts. Our findings show that while some fibrotic markers did decrease in …
- グルタレドキシンとピルフェニドンの併用による線維化マーカー低下効果の検討
Utilizing Biomaterials to Mimic Lung Diseases and Understand Cellular Repair Mechanisms
B Gamber - 2024
… There is a significant gap in the knowledge surrounding cellular and molecular lung repair which in turn has delayed advancement of therapeutic approaches for IPF. The implementation of novel human lung-derived biomaterials that mimic …
- 生体材料を利用して肺疾患を模倣し、細胞修復メカニズムを理解する
Using Artificial Intelligence to Identify TRAF2-and NCK-Interacting Kinase as a Target for Fibrosis
AF Stepan, NA Meanwell - Synfacts, 2024
… a potential target for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF) for which the composite data suggested a close … Although INS018_55 is active in animal models of IPF, efficacy in a clinical setting is required …
- 人工知能を使用して TRAF2 と NCK 相互作用キナーゼを線維症の標的として特定する
24/06/16
Novel Small Molecule ROCK2 Inhibitor GNS-3595 Attenuates Pulmonary Fibrosis in Preclinical Studies
S Hwang, W Lee, D Ravi, W Devine, M Yong… - American Journal of …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that leads to respiratory decline … of RhoA, is overexpressed in IPFpatients and is a promising target for IPF therapy. However, due to … Additionally, in a bleomycin-induced …
- 新規小分子ROCK2阻害剤GNS-3595が前臨床研究で肺線維症を軽減
[HTML] Stem Cell Therapy for Pulmonary Fibrosis
H Hunt
… of the fibrotic process of IPF has led to studies exploring … pulmonary fibrosis (PF) in animal models and IPF patients. Search Methods: An online search in the PubMed database was conducted from February to April of 2024 the following …
- 肺線維症に対する幹細胞療法
[HTML] Realveolarization with inhalable mucus-penetrating lipid nanoparticles for the treatment of pulmonary fibrosis in mice
Y Wang, J Zhang, Y Liu, X Yue, K Han, Z Kong, Y Dong… - Science Advances, 2024
… The stemness loss–associated dysregeneration of impaired alveolar type 2 epithelial (AT2) cells abolishes the reversible therapy of idiopathic pulmonary fibrosis (IPF). We here report an inhalable mucus-penetrating lipid nanoparticle (LNP) …
- マウスの肺線維症の治療のための吸入可能な粘液浸透性脂質ナノ粒子による再胞化
[PDF] Paving the ROCKy Path to Novel Anti-Fibrotics
RS Knipe, R Gosens - American Journal of Respiratory Cell and Molecular …, 2024
… pulmonary fibrosis is unrealized. Ther are concerns about potential side effects of panROCK inhibitors, especially with chronic use t for a patient with idiopathic pulmonary fibrosis(IPF). … However, ROCK inhibitors are untested in clinical trials …
- 新たな抗線維化薬への険しい道を切り開く
<>
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
